Blowing smoke: 5 pervasive pot myths debunked
There’s a glut of misinformation out there about weed.
In fact, misconceptions have trailed the cannabis plant across the history of prohibition, underpinning policy itself and anti-marijuana propaganda — as with the Reefer Madness film cycle in the US and corresponding alarmist sentiment.
Moreover, these pervasive pot myths — many of which reflect deeper socio-cultural anxieties around issues like race, class, mental health and criminality — contribute to stigma around pot that’s still very real.
This, in turn, has kept many in the dark about the significant benefits of cannabis — something that’s only quite recently becoming more widely understood as an increasingly permissive legislative landscape emerges.
Here, we dispel some of the most common myths about pot to clear the haze.
1 - You can fatally overdose on weed
While prescription painkillers cause thousands of overdose deaths each year, no one has ever died from a marijuana overdose. In fact, one of the major upsides of medicinal cannabis — alongside the catalogue of therapeutic benefits that can come with it — is that it’s virtually impossible to fatally overdose.
Because cannabinoid receptors aren’t located in the brainstem areas controlling respiration, unlike opioid receptors, lethal overdoses from cannabis and cannabinoids don’t occur. In other words, pot and opioids affect different pathways of the body. Opioid pathways, also known as receptors, are present in areas of the brain that control breathing. As a result, taking too many painkillers can cause a person to stop breathing.
Marijuana, however, acts on a completely different set of pathways — these are called cannabinoid receptors and don’t affect respiration. Pot can’t cause you to stop breathing, no matter how much you ingest.
Interconnectedly, another way of explaining this relates to the endocannabidonoid system (ECS) – one of the most crucial physiologic systems at play in establishing and maintaining human health.
The ECS is responsible for modulating every other body system from the bones to the central nervous system. Without it, we wouldn’t get the therapeutic benefits from pot, or the high that’s associated with it.
While the ECS is linked to a range of crucial processes and is concentrated in the brain, nervous system and reproductive organs, it doesn’t affect regions of the brain controlling heart and lung function. This, in turn, is one of the main reasons that fatal overdoses from cannabis and cannabinoids don’t occur.
2 - It kills brain cells
This one makes for one of the most popular arguments against pot use — both for freaked out parents and actual would-be law-makers.
After many decades of back-and-forth studies, 2015 research by University of Louisville has determined that pot use does not destroy brain cells. This also corroborates a 2003 report in the Journal of the International Neuropsychological Society published by Cambridge University making the same claim.
Note, though, that findings in a review of studies whose subjects reported ‘chronic’ and ‘heavy’ cannabis use suggest an association with deficits in cognitive functions such as decision-making, concept formation and planning after periods of abstinence of three weeks or more. What constitutes ‘chronic’ and ‘heavy’ use, however, is not clearly defined.
As with everything, moderation is clearly key.
3 - It’s a gateway drug
Of all the arguments that have been used to demonise weed, few have been more powerful than that of the so-called ‘gateway effect’: the idea that while pot itself may not be especially dangerous, it inevitably leads to ‘harder’ drugs like heroin and cocaine.
This narrative seems to have properly taken hold in the 1960s, when pot most visibly emerged as a popular recreational drug. It went on to become the mainstay of many alarmist anti-drug high school programs.
However, it seems to have no scientific groundings. A report by the Institute of Medicine states that "no conclusive evidence that the drug effects of marijuana are causally linked to the subsequent abuse of other illicit drugs".
It’s also worth noting that because it is the most widely used illicit drug, marijuana is predictably the first illicit drug most people encounter.
Moreover, most pot users never go on to try or use illicit drugs. In fact, most drug use begins with alcohol and nicotine before marijuana, making these the two most common drugs of abuse.
Correspondingly, a study published in the peer-reviewed Journal of School Health has concluded that the gateway drug theory is not associated with cannabis, but rather with alcohol – one of the most damaging yet socially accepted drugs. The findings from this study support that alcohol should receive primary attention in abuse prevention programming, since the use of other substances could be impacted by delaying or preventing alcohol use.
4 - Pot is just about getting high
This is one of the longest standing misconceptions about pot — and one which precludes the many medical cannabis medications that are non-psychoactive.
The idea seems to be bound up in unclear information about how various cannabinoids operate – specifically, the differences between THC (tetrahydrocannabinol) and CBD (cannabidiol).
CBD and THC are two of over 60 compounds found in cannabis that belong to a class of molecules called cannabinoids. They’re usually present in the highest concentrations, and are therefore the most widely studied.
Both have a variety of uses for medicinal purposes, but only one of them produces the buzz or high commonly associated with pot — THC, which produces a psychoactive effect.
CBD has significant medical benefits, but isn’t mind-altering per se. Rather, CBD can have a sedative, relaxing effect — and, interestingly, it can also counteract the psychoactivity of THC.
CBD is non-psychoactive because it does not act on the same neuronal pathways as THC. These pathways, called CB1 receptors, are highly concentrated in the brain and are responsible for the mind-altering effects of THC.
In turn, the fact that CBD-rich cannabis strains don’t induce a high makes them a particularly appealing treatment option for patients seeking anti-inflammatory, anti-pain, anti-anxiety, anti-psychotic, and/or anti-spasm effects without the mind-altering effects of THC.
5 - Cannabis is addictive
Research suggests that about 9% of marijuana users became clinically dependent at some point, compared to 15% of cocaine users and 24% of heroin users.
It’s also important to note that cannabis isn’t physically addictive like heroin, cocaine or tobacco. Coffee (or caffeine specifically) is actually more addictive than pot.
With that in mind, cannabis in and of itself isn’t addictive, but roughly 10% of habitual users develop what’s known as a cannabis use disorder.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.